{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:09:38Z","timestamp":1774530578402,"version":"3.50.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Polish National Science Centre","doi-asserted-by":"crossref","award":["DEC-2021\/05\/X\/NZ7\/01292"],"award-info":[{"award-number":["DEC-2021\/05\/X\/NZ7\/01292"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38418-6","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T02:35:37Z","timestamp":1771641337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a UPLC-MS\/MS method and its application for the pharmacokinetic analysis of regorafenib in rats"],"prefix":"10.1038","volume":"16","author":[{"given":"Filip","family":"Otto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoriia","family":"Propisnova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Urjasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konrad","family":"Sarnowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edyta","family":"Sza\u0142ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Karbownik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"issue":"11","key":"38418_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/17425255.2023.2272598","volume":"19","author":"R Borriello","year":"2023","unstructured":"Borriello, R., Cerrito, L., Gasbarrini, A. & Ponziani, F. R. Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview. Expert Opin. Drug Metab. Toxicol. 19 (11), 785\u2013794 (2023).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"38418_CR2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm, S. M. et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer. 129 (1), 245\u2013255 (2011).","journal-title":"Int. J. Cancer"},{"issue":"7","key":"38418_CR3","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","volume":"12","author":"L Abou-Elkacem","year":"2013","unstructured":"Abou-Elkacem, L. et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol. Cancer Ther. 12 (7), 1322\u20131331 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"38418_CR4","unstructured":"European Medicines Agency. Stivarga, summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stivarga-epar-product-information_en.pdf"},{"key":"38418_CR5","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1017\/erm.2024.8","volume":"26","author":"MP Mongiardi","year":"2024","unstructured":"Mongiardi, M. P., Pallini, R., D\u2019Alessandris, Q. G., Levi, A. & Falchetti, M. L. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness. Expert Rev. Mol. Med. 26, e5. https:\/\/doi.org\/10.1017\/erm.2024.8 (2024).","journal-title":"Expert Rev. Mol. Med."},{"issue":"14","key":"38418_CR6","first-page":"5008","volume":"26","author":"M De Felice","year":"2022","unstructured":"De Felice, M. et al. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature. Eur. Rev. Med. Pharmacol. Sci. 26 (14), 5008\u20135013 (2022).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"3","key":"38418_CR7","doi-asserted-by":"publisher","first-page":"101569","DOI":"10.1016\/j.esmoop.2023.101569","volume":"8","author":"A Le Cesne","year":"2023","unstructured":"Le Cesne, A. et al. Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open. 8 (3), 101569. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101569 (2023).","journal-title":"ESMO Open."},{"issue":"2","key":"38418_CR8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cam4.5044","volume":"12","author":"S Attia","year":"2023","unstructured":"Attia, S. et al. A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results. Cancer Med. 12 (2), 1532\u20131539 (2023).","journal-title":"Cancer Med."},{"key":"38418_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","volume":"162","author":"S Cousin","year":"2022","unstructured":"Cousin, S. et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur. J. Cancer. 162, 161\u2013169 (2022).","journal-title":"Eur. J. Cancer"},{"key":"38418_CR10","doi-asserted-by":"publisher","first-page":"113391","DOI":"10.1016\/j.ejca.2023.113391","volume":"195","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti, S. et al. Regorafenib in advanced solitary fibrous tumour: results from an exploratory phase II clinical study. Eur. J. Cancer. 195, 113391. https:\/\/doi.org\/10.1016\/j.ejca.2023.113391 (2023).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"38418_CR11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/CMR.0000000000000977","volume":"34","author":"AS Vander Mijnsbrugge","year":"2024","unstructured":"Vander Mijnsbrugge, A. S. et al. Regorafenib in patients with pretreated advanced melanoma: a single-center case series. Melanoma Res. 34 (4), 366\u2013375 (2024).","journal-title":"Melanoma Res."},{"issue":"10","key":"38418_CR12","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S1470-2045(23)00358-3","volume":"24","author":"SL Cytryn","year":"2023","unstructured":"Cytryn, S. L. et al. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Lancet Oncol. 24 (10), 1073\u20131082 (2023).","journal-title":"Lancet Oncol."},{"issue":"8","key":"38418_CR13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5483\/BMBRep.2023-0072","volume":"56","author":"K Oh","year":"2023","unstructured":"Oh, K. et al. Regorafenib prevents the development of emphysema in a murine elastase model. BMB Rep. 56 (8), 439\u2013444 (2023).","journal-title":"BMB Rep."},{"issue":"4","key":"38418_CR14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s12276-023-00966-6","volume":"55","author":"JJ Park","year":"2023","unstructured":"Park, J. J. et al. Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema. Exp. Mol. Med. 55 (4), 794\u2013805 (2023).","journal-title":"Exp. Mol. Med."},{"key":"38418_CR15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","volume":"169","author":"RD Kim","year":"2022","unstructured":"Kim, R. D. et al. A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur. J. Cancer. 169, 93\u2013102 (2022).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"38418_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13046-024-03106-8","volume":"43","author":"P Bajpai","year":"2024","unstructured":"Bajpai, P. et al. Combination of dual JAK\/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer. J. Exp. Clin. Cancer Res. 43 (1), 192. https:\/\/doi.org\/10.1186\/s13046-024-03106-8 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"38418_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1186\/s12877-022-03637-9","volume":"22","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer. BMC Geriatr. 22 (1), 987. https:\/\/doi.org\/10.1186\/s12877-022-03637-9 (2022).","journal-title":"BMC Geriatr."},{"issue":"8","key":"38418_CR18","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","volume":"27","author":"S Cousin","year":"2021","unstructured":"Cousin, S. et al. Regorafenib-avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial. Clin. Cancer Res. 27 (8), 2139\u20132147 (2021).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"38418_CR19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/CAD.0000000000001273","volume":"33","author":"C Alanda\u011f","year":"2022","unstructured":"Alanda\u011f, C., Karaman, E. & Y\u00fcce, E. Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer. Anticancer Drugs. 33 (4), 389\u2013393 (2022).","journal-title":"Anticancer Drugs"},{"issue":"1","key":"38418_CR20","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00280-017-3480-9","volume":"81","author":"M Gerisch","year":"2018","unstructured":"Gerisch, M. et al. Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects. Cancer Chemother. Pharmacol. 81 (1), 195\u2013206 (2018).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"38418_CR21","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1002\/cam4.883","volume":"5","author":"D Zopf","year":"2016","unstructured":"Zopf, D. et al. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models. Cancer Med. 5 (11), 3176\u20133185 (2016).","journal-title":"Cancer Med."},{"issue":"9","key":"38418_CR22","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","volume":"18","author":"K Mross","year":"2012","unstructured":"Mross, K. et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 18 (9), 2658\u20132667 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"38418_CR23","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11095-014-1609-7","volume":"32","author":"A Kort","year":"2015","unstructured":"Kort, A. et al. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1). Pharm. Res. 32 (7), 2205\u20132216 (2015).","journal-title":"Pharm. Res."},{"issue":"9","key":"38418_CR24","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.xphs.2017.04.064","volume":"106","author":"KI Fujita","year":"2017","unstructured":"Fujita, K. I. et al. Involvement of the transporters P-glycoprotein and breast cancer resistance protein in dermal distribution of the multikinase inhibitor regorafenib and its active metabolites. J. Pharm. Sci. 106 (9), 2632\u20132641 (2017).","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"38418_CR25","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.xphs.2019.01.018","volume":"108","author":"AH Al-Shammari","year":"2019","unstructured":"Al-Shammari, A. H. et al. Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration in mice. J. Pharm. Sci. 108 (6), 2173\u20132179 (2019).","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"38418_CR26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","volume":"41","author":"M Herbrink","year":"2015","unstructured":"Herbrink, M., Nuijen, B., Schellens, J. H. M. & Beijnen, J. H. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat. Rev. 41 (5), 412\u2013422 (2015).","journal-title":"Cancer Treat. Rev."},{"key":"38418_CR27","unstructured":"DrugBank Online. Regorafenib: uses, interactions, mechanism of action. https:\/\/go.drugbank.com\/drugs\/DB08896"},{"issue":"17","key":"38418_CR28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","volume":"77","author":"J Deng","year":"2017","unstructured":"Deng, J. et al. A review of food-drug interactions on oral drug absorption. Drugs 77 (17), 1833\u20131855 (2017).","journal-title":"Drugs"},{"issue":"5","key":"38418_CR29","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S1470-2045(20)30069-3","volume":"21","author":"GDM Veerman","year":"2020","unstructured":"Veerman, G. D. M. et al. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol. 21 (5), e265\u2013e279. https:\/\/doi.org\/10.1016\/S1470-2045(20)30069-3 (2020).","journal-title":"Lancet Oncol."},{"issue":"12","key":"38418_CR30","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/cpdd.1474","volume":"13","author":"Z Wang","year":"2024","unstructured":"Wang, Z., Zhang, Y., Liu, J. & Chen, X. Bioequivalence and pharmacokinetic evaluation of regorafenib tablets in healthy Chinese volunteers. Clin. Pharmacol. Drug Dev. 13 (12), 1317\u20131323 (2024).","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"12","key":"38418_CR31","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/bcp.14334","volume":"86","author":"A Keunecke","year":"2020","unstructured":"Keunecke, A. et al. Population pharmacokinetics of regorafenib in solid tumours: exposure in clinical practice considering enterohepatic circulation and food intake. Br. J. Clin. Pharmacol. 86 (12), 2362\u20132376 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"38418_CR32","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cpt.1810","volume":"108","author":"Y Kubota","year":"2020","unstructured":"Kubota, Y. et al. Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. Clin. Pharmacol. Ther. 108 (3), 586\u2013595 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"38418_CR33","unstructured":"European Medicines Agency. ICH guideline M10 on bioanalytical method validation and study sample analysis, (2022). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf"},{"issue":"5","key":"38418_CR34","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s43440-024-00570-z","volume":"76","author":"D Szkutnik-Fiedler","year":"2024","unstructured":"Szkutnik-Fiedler, D. et al. Pharmacokinetic interaction between regorafenib and atorvastatin in rats. Pharmacol. Rep. 76 (5), 1184\u20131195 (2024).","journal-title":"Pharmacol. Rep."},{"key":"38418_CR35","doi-asserted-by":"publisher","first-page":"1136735","DOI":"10.3389\/fphar.2023.1136735","volume":"14","author":"S Lu","year":"2023","unstructured":"Lu, S., Zhao, M., Zhao, L. & Li, G. Development of a UPLC-MS\/MS method for simultaneous therapeutic drug monitoring of anti-hepatocellular carcinoma drugs and analgesics in human plasma. Front. Pharmacol. 14, 1136735. https:\/\/doi.org\/10.3389\/fphar.2023.1136735 (2023).","journal-title":"Front. Pharmacol."},{"issue":"5","key":"38418_CR36","doi-asserted-by":"publisher","first-page":"e2300923","DOI":"10.1002\/jssc.202300923","volume":"47","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. Exploring the effect of Wuzhi capsule on the pharmacokinetics of regorafenib and its main metabolites in rat plasma using liquid chromatography-tandem mass spectrometry. J. Sep. Sci. 47 (5), e2300923. https:\/\/doi.org\/10.1002\/jssc.202300923 (2024).","journal-title":"J. Sep. Sci."},{"key":"38418_CR37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jchromb.2018.02.008","volume":"1083","author":"E Cardoso","year":"2018","unstructured":"Cardoso, E. et al. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. 1083, 124\u2013136 (2018).","journal-title":"J. Chromatogr. B"},{"key":"38418_CR38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpba.2017.04.053","volume":"142","author":"M Allard","year":"2017","unstructured":"Allard, M. et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS\/MS. J. Pharm. Biomed. Anal. 142, 42\u201348 (2017).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"4","key":"38418_CR39","doi-asserted-by":"publisher","first-page":"e4147","DOI":"10.1002\/bmc.4147","volume":"32","author":"M Herbrink","year":"2018","unstructured":"Herbrink, M. et al. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed. Chromatogr. 32 (4), e4147. https:\/\/doi.org\/10.1002\/bmc.4147 (2018).","journal-title":"Biomed. Chromatogr."},{"key":"38418_CR40","doi-asserted-by":"publisher","first-page":"124100","DOI":"10.1016\/j.jchromb.2024.124100","volume":"1237","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS\/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. J. Chromatogr. B. 1237, 124100. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124100 (2024).","journal-title":"J. Chromatogr. B"},{"key":"38418_CR41","doi-asserted-by":"publisher","unstructured":"Krens, S. D., van der Meulen, E., Jansman, F. G. A., Burger, D. M. & van Erp, N. P. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS\/MS. Biomed. Chromatogr. 34 (3). https:\/\/doi.org\/10.1002\/bmc.4758 (2020). e4758.","DOI":"10.1002\/bmc.4758"},{"key":"38418_CR42","doi-asserted-by":"publisher","first-page":"113358","DOI":"10.1016\/j.jpba.2020.113358","volume":"187","author":"V Iacuzzi","year":"2020","unstructured":"Iacuzzi, V. et al. A LC-MS\/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma. J. Pharm. Biomed. Anal. 187, 113358. https:\/\/doi.org\/10.1016\/j.jpba.2020.113358 (2020).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"38418_CR43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jchromb.2013.08.013","volume":"937","author":"NP van Erp","year":"2013","unstructured":"van Erp, N. P. et al. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B. 937, 33\u201343 (2013).","journal-title":"J Chromatogr B"},{"key":"38418_CR44","doi-asserted-by":"publisher","first-page":"114517","DOI":"10.1016\/j.jpba.2021.114517","volume":"212","author":"G Li","year":"2022","unstructured":"Li, G., Zhao, M. & Zhao, L. Development and validation of an UPLC-MS\/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring. J. Pharm. Biomed. Anal. 212, 114517. https:\/\/doi.org\/10.1016\/j.jpba.2021.114517 (2022).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"38418_CR45","doi-asserted-by":"publisher","first-page":"920436","DOI":"10.3389\/fphar.2022.920436","volume":"13","author":"W Jiang","year":"2022","unstructured":"Jiang, W. et al. Rapid determination of 9 tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma in human plasma by QuEChERS-UPLC-MS\/MS. Front. Pharmacol. 13, 920436. https:\/\/doi.org\/10.3389\/fphar.2022.920436 (2022).","journal-title":"Front. Pharmacol."},{"issue":"10","key":"38418_CR46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4155\/bio-2017-0028","volume":"9","author":"JE Romero","year":"2017","unstructured":"Romero, J. E., Chiva, J. A., Peris-Vicente, J. & Ochoa-Aranda, E. Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma. Bioanalysis 9 (10), 799\u2013812 (2017).","journal-title":"Bioanalysis"},{"key":"38418_CR47","doi-asserted-by":"publisher","first-page":"114562","DOI":"10.1016\/j.jpba.2021.114562","volume":"211","author":"M Zhang","year":"2022","unstructured":"Zhang, M. et al. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma\/serum using UPLC-MS\/MS for therapeutic drug monitoring. J. Pharm. Biomed. Anal. 211, 114562. https:\/\/doi.org\/10.1016\/j.jpba.2021.114562 (2022).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"38418_CR48","doi-asserted-by":"publisher","first-page":"955263","DOI":"10.3389\/fphar.2022.955263","volume":"13","author":"EM Gu","year":"2022","unstructured":"Gu, E. M. et al. A high throughput method for monitoring of sorafenib, regorafenib, cabozantinib and their metabolites with UPLC-MS\/MS in rat plasma. Front. Pharmacol. 13, 955263. https:\/\/doi.org\/10.3389\/fphar.2022.955263 (2022).","journal-title":"Front. Pharmacol."},{"issue":"24","key":"38418_CR49","doi-asserted-by":"publisher","first-page":"6329","DOI":"10.3390\/cancers13246329","volume":"13","author":"N Kehl","year":"2021","unstructured":"Kehl, N. et al. An easily expandable multi-drug LC-MS assay for the simultaneous quantification of 57 oral antitumor drugs in human plasma. Cancers 13 (24), 6329. https:\/\/doi.org\/10.3390\/cancers13246329 (2021).","journal-title":"Cancers"},{"issue":"5","key":"38418_CR50","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1007\/s10637-021-01115-4","volume":"39","author":"M Fukudo","year":"2021","unstructured":"Fukudo, M. et al. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes. Invest. New. Drugs. 39 (5), 1422\u20131431 (2021).","journal-title":"Invest. New. Drugs"},{"issue":"10","key":"38418_CR51","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/bmc.3730","volume":"30","author":"K Fujita","year":"2016","unstructured":"Fujita, K., Miura, M. & Shibata, H. Quantitative determination of regorafenib and its two major metabolites in human plasma with high-performance liquid chromatography and ultraviolet detection. Biomed. Chromatogr. 30 (10), 1611\u20131617 (2016).","journal-title":"Biomed. Chromatogr."},{"issue":"3","key":"38418_CR52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s44211-022-00068-9","volume":"38","author":"S Li","year":"2022","unstructured":"Li, S. et al. Development and validation of a simple and sensitive HPLC method for the determination of related substances in regorafenib tablets. Anal. Sci. 38 (3), 591\u2013599 (2022).","journal-title":"Anal. Sci."},{"key":"38418_CR53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.53879\/id.55.06.11047","volume":"55","author":"R Raut","year":"2018","unstructured":"Raut, R. et al. Reverse phase high performance liquid chromatographic method for determination of regorafenib in tablet dosage form. Indian Drugs. 55, 63\u201368 (2018).","journal-title":"Indian Drugs"},{"key":"38418_CR54","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/bkcs.12355","volume":"42","author":"JS Kim","year":"2021","unstructured":"Kim, J. S., Cho, J. H. & Choi, H. G. Development of a simple, precise, and validated HPLC method for the anticancer drug, regorafenib: application to pharmacokinetics in rats and stability study. Bull. Korean Chem. Soc. 42, 1239\u20131244 (2021).","journal-title":"Bull. Korean Chem. Soc."},{"issue":"1","key":"38418_CR55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40478-020-00953-2","volume":"8","author":"AS Guntner","year":"2020","unstructured":"Guntner, A. S. et al. Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol. Commun. 8 (1), 78. https:\/\/doi.org\/10.1186\/s40478-020-00953-2 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"38418_CR56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jchromb.2017.07.023","volume":"1061","author":"YY Pang","year":"2017","unstructured":"Pang, Y. Y., Tan, Y. L. & Ho, H. K. Investigation of the effect of plasma albumin levels on regorafenib-induced hepatotoxicity using a validated liquid chromatography-tandem mass spectrometry method. J. Chromatogr. B. 1061, 220\u2013224 (2017).","journal-title":"J. Chromatogr. B"},{"issue":"4","key":"38418_CR57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcpt.13246","volume":"125","author":"YH Li","year":"2019","unstructured":"Li, Y. H. et al. Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro. Basic. Clin. Pharmacol. Toxicol. 125 (4), 337\u2013344 (2019).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"issue":"14","key":"38418_CR58","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4155\/bio.14.52","volume":"6","author":"FT Hafner","year":"2014","unstructured":"Hafner, F. T., Werner, D. & Kaiser, M. Determination of regorafenib (BAY 73-4506) and its major human metabolites BAY 75-7495 (M-2) and BAY 81-8752 (M-5) in human plasma by stable-isotope dilution liquid chromatography-tandem mass spectrometry. Bioanalysis 6 (14), 1923\u20131937 (2014).","journal-title":"Bioanalysis"},{"key":"38418_CR59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2018.05.005","volume":"1090","author":"Q Fu","year":"2018","unstructured":"Fu, Q. et al. Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma. J. Chromatogr. B. 1090, 43\u201351 (2018).","journal-title":"J. Chromatogr. B"},{"key":"38418_CR60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","volume":"150","author":"C Merienne","year":"2018","unstructured":"Merienne, C. et al. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS\/MS. J. Pharm. Biomed. Anal. 150, 112\u2013120 (2018).","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"10","key":"38418_CR61","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/bmc.3176","volume":"28","author":"D Luethi","year":"2014","unstructured":"Luethi, D. et al. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomed. Chromatogr. 28 (10), 1366\u20131370 (2014).","journal-title":"Biomed. Chromatogr."},{"issue":"12","key":"38418_CR62","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/jcm8122031","volume":"8","author":"PS Zeiner","year":"2019","unstructured":"Zeiner, P. S. et al. Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients. J. Clin. Med. 8 (12), 2031. https:\/\/doi.org\/10.3390\/jcm8122031 (2019).","journal-title":"J. Clin. Med."},{"issue":"6","key":"38418_CR63","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-021-04237-x","volume":"87","author":"K Kobayashi","year":"2021","unstructured":"Kobayashi, K. et al. Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemother. Pharmacol. 87 (6), 767\u2013777 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"38418_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clcc.2019.10.004","volume":"19","author":"T Suzuki","year":"2020","unstructured":"Suzuki, T. et al. A phase II study of regorafenib with a lower starting dose in patients with metastatic colorectal cancer: exposure-toxicity analysis of unbound regorafenib and its active metabolites (RESET Trial). Clin. Colorectal Cancer. 19 (1), 13\u201321e. https:\/\/doi.org\/10.1016\/j.clcc.2019.10.004 (2020).","journal-title":"Clin. Colorectal Cancer"},{"issue":"11","key":"38418_CR65","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/pharmaceutics16111387","volume":"16","author":"A Karbownik","year":"2024","unstructured":"Karbownik, A. et al. A Pharmacokinetic study of the interaction between regorafenib and paracetamol in male rats. Pharmaceutics 16 (11), 1387. https:\/\/doi.org\/10.3390\/pharmaceutics16111387 (2024).","journal-title":"Pharmaceutics"},{"key":"38418_CR66","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00280-018-3710-9","volume":"83","author":"A Maeda","year":"2019","unstructured":"Maeda, A. et al. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphism. Cancer Chemother. Pharmacol. 83, 107\u2013113. https:\/\/doi.org\/10.1007\/s00280-018-3710-9 (2019).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"38418_CR67","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1248\/bpb.b14-00740","volume":"38","author":"H Ohya","year":"2015","unstructured":"Ohya, H. et al. Regorafenib is transported by the organic anion transporter 1B1 and the multidrug resistance protein 2. Biol. Pharm. Bull. 38, 582\u2013586 (2015).","journal-title":"Biol. Pharm. Bull."},{"key":"38418_CR68","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s11095-014-1609-7","volume":"32","author":"A Kort","year":"2015","unstructured":"Kort, A. et al. Brain and testis accumulation of regorafenib is restricted by breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1). Pharm. Res. 32, 2205\u20132216 (2015).","journal-title":"Pharm. Res."},{"key":"38418_CR69","first-page":"4681","volume":"35","author":"K Hotta","year":"2015","unstructured":"Hotta, K. et al. Lack of contribution of multidrug resistance-associated protein and organic anion-transporting polypeptide to pharmacokinetics of regorafenib, a novel multi-kinase inhibitor, in rats. Anticancer Res. 35, 4681\u20134689 (2015).","journal-title":"Anticancer Res."},{"issue":"3","key":"38418_CR70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41397-021-00208-w","volume":"21","author":"S Turongkaravee","year":"2021","unstructured":"Turongkaravee, S. et al. A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy. Pharmacogenomics J. 21 (3), 296\u2013307 (2021).","journal-title":"Pharmacogenomics J."},{"key":"38418_CR71","unstructured":"Gilani, B., Cassagnol, M. & Biochemistry, Cytochrome, P. in: StatPearls, Treasure Island (FL), StatPearls Publishing (2025). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557698"},{"key":"38418_CR72","unstructured":"European Medicines Agency. Mekinist, summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mekinist-epar-product-information_en.pdf"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38418-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38418-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38418-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:35:32Z","timestamp":1774528532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38418-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38418"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38418-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The experimental design and reporting followed the ARRIVE guidelines to ensure transparency and reproducibility. Based on these principles, a detailed experimental protocol was prepared and submitted for ethical review. The study was subsequently approved by the Local Ethics Committee (Department of Animal Physiology and Biochemistry, Pozna\u0144 University of Life Sciences, Wo\u0142y\u0144ska 35, 60\u2013637 Pozna\u0144, Poland; approval no. 40\/2023).\u00a0All subsequent procedures, including animal housing and care, dosing regimen, blood sampling, and euthanasia, were conducted strictly in accordance with this approved protocol, ensuring full compliance with both institutional and international standards for animal research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"10108"}}